Pulmonary Complications of Cirrhosis

Medical Clinics of North America

Volumn 93, Issue 4, 2009, Pages 871-883

  Singh, C ^a   Sager, J S ^b  

^a SANTA BARBARA COTTAGE HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Hepatic hydrothorax; Hepatopulmonary syndrome; Liver transplantation; Portopulmonary hypertension; Pulmonary hypertension

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CYCLOPHOSPHAMIDE; ILOPROST; METHYLENE BLUE; NITRIC OXIDE; OCTREOTIDE; PROSTACYCLIN; SILDENAFIL; STEROID; TERLIPRESSIN; VASODILATOR AGENT;

CLINICAL FEATURE; DETERIORATION; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; HEPATIC HYDROTHORAX; HEPATOPULMONARY SYNDROME; HUMAN; HYDROTHORAX; HYPOXEMIA; INTRAPULMONARY VASCULAR DILATATION; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; OXYGEN DIFFUSION; OXYGENATION; PATHOGENESIS; PATHOPHYSIOLOGY; PLEURODESIS; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTOPENIA; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VASODILATATION;

DIAGNOSIS, DIFFERENTIAL; ECHOCARDIOGRAPHY, DOPPLER; HEPATOPULMONARY SYNDROME; HUMANS; HYDROTHORAX; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PROGNOSIS;

EID: 67649415005     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2009.03.006     Document Type: Review

References (65)

1. Kung H.C., Hoyert D.L., Xu J., et al. Deaths: final data for 2005. Natl Vital Stat Rep 56 10 (2008) 1-120
2. King P.D., Rumbaut R., and Sanchez C. Pulmonary manifestations of chronic liver disease. Dig Dis 14 2 (1996) 73-82
3. Kennedy T.C., and Knudson R.J. Exercise-aggravated hypoxemia and orthodeoxia in cirrhosis. Chest 72 3 (1977) 305-309
4. Schenk P., Fuhrmann V., Madl C., et al. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut 51 6 (2002) 853-859
5. Swanson K.L., Wiesner R.H., and Krowka M.J. Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology 41 5 (2005) 1122-1129
6. Schiffer E., Majno P., Mentha G., et al. Hepatopulmonary syndrome increases the postoperative mortality rate following liver transplantation: a prospective study in 90 patients. Am J Transplant 6 6 (2006) 1430-1437
7. Rodriguez-Roisin R., and Krowka M.J. Hepatopulmonary syndrome-a liver-induced lung vascular disorder. N Engl J Med 358 22 (2008) 2378-2387
8. Krowka M.J., and Cortese D.A. Hepatopulmonary syndrome: an evolving perspective in the era of liver transplantation. Hepatology 11 1 (1990) 138-142
9. Zhang H.Y., Han de W., Su A.R., et al. Intestinal endotoxemia plays a central role in development of hepatopulmonary syndrome in a cirrhotic rat model induced by multiple pathogenic factors. World J Gastroenterol 13 47 (2007) 6385-6395
10. Bruix J., Bosch J., Kravetz D., et al. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 88 2 (1985) 430-435
11. Zipser R.D., Hoefs J.C., Speckart P.F., et al. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 48 6 (1979) 895-900
12. Fallon M.B., Abrams G.A., Luo B., et al. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 113 2 (1997) 606-614
13. Tang L., Luo B., Patel R.P., et al. Modulation of pulmonary endothelial endothelin B receptor expression and signaling: implications for experimental hepatopulmonary syndrome. Am J Physiol Lung Cell Mol Physiol 292 6 (2007) L1467-L1472
14. Schenk P., Madl C., Rezaie-Majd S., et al. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 133 9 (2000) 701-706
15. Nunes H., Lebrec D., Mazmanian M., et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med 164 5 (2001) 879-885
16. Rolla G., Brussino L., Colagrande P., et al. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology 26 4 (1997) 842-847
17. Cremona G., Higenbottam T.W., Mayoral V., et al. Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome. Eur Respir J 8 11 (1995) 1883-1885
18. Whyte M.K., Hughes J.M., Peters A.M., et al. Analysis of intrapulmonary right to left shunt in the hepatopulmonary syndrome. J Hepatol 29 1 (1998) 85-93
19. Edell E.S., Cortese D.A., Krowka M.J., et al. Severe hypoxemia and liver disease. Am Rev Respir Dis 140 6 (1989) 1631-1635
20. Martinez G.P., Barbera J.A., Visa J., et al. Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol 34 5 (2001) 651-657
21. Rodriguez-Roisin R., Roca J., Agusti A.G., et al. Gas exchange and pulmonary vascular reactivity in patients with liver cirrhosis. Am Rev Respir Dis 135 5 (1987) 1085-1092
22. Krowka M.J., Wiseman G.A., Burnett O.L., et al. Hepatopulmonary syndrome: a prospective study of relationships between severity of liver disease, PaO(2) response to 100% oxygen, and brain uptake after (99m)Tc MAA lung scanning. Chest 118 3 (2000) 615-624
23. Henriksen J.H., Ring-Larsen H., and Christensen N.J. Circulating noradrenaline and central haemodynamics in patients with cirrhosis. Scand J Gastroenterol 20 10 (1985) 1185-1190
24. Thorens J.B., and Junod A.F. Hypoxaemia and liver cirrhosis: a new argument in favour of a "diffusion-perfusion defect". Eur Respir J 5 6 (1992) 754-756
25. Robin E.D., Laman D., Horn B.R., et al. Platypnea related to orthodeoxia caused by true vascular lung shunts. N Engl J Med 294 17 (1976) 941-943
26. Gomez F.P., Martinez-Palli G., Barbera J.A., et al. Gas exchange mechanism of orthodeoxia in hepatopulmonary syndrome. Hepatology 40 3 (2004) 660-666
27. Rodriguez-Roisin R., Krowka M.J., Herve P., et al. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 24 5 (2004) 861-880
28. Krowka M.J., Dickson E.R., and Cortese D.A. Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. Chest 104 2 (1993) 515-521
29. Martinez-Palli G., Gomez F.P., Barbera J.A., et al. Sustained low diffusing capacity in hepatopulmonary syndrome after liver transplantation. World J Gastroenterol 12 36 (2006) 5878-5883
30. Battaglia S.E., Pretto J.J., Irving L.B., et al. Resolution of gas exchange abnormalities and intrapulmonary shunting following liver transplantation. Hepatology 25 5 (1997) 1228-1232
31. Abrams G.A., Nanda N.C., Dubovsky E.V., et al. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology 114 2 (1998) 305-310
32. Krowka M.J., Tajik A.J., Dickson E.R., et al. Intrapulmonary vascular dilatations (IPVD) in liver transplant candidates. Screening by two-dimensional contrast-enhanced echocardiography. Chest 97 5 (1990) 1165-1170
33. Poterucha J.J., Krowka M.J., Dickson E.R., et al. Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy. Hepatology 21 1 (1995) 96-100
34. Taille C., Cadranel J., Bellocq A., et al. Liver transplantation for hepatopulmonary syndrome: a ten-year experience in Paris, France. Transplantation 75 9 (2003) 1482-1489 [discussion: 1446-87]
35. Almeida J.A., Riordan S.M., Liu J., et al. Deleterious effect of nitric oxide inhibition in chronic hepatopulmonary syndrome. Eur J Gastroenterol Hepatol 19 4 (2007) 341-346
36. Mantz Jr. F.A., and Craige E. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. AMA Arch Pathol 52 1 (1951) 91-97
37. Hoeper M.M., Krowka M.J., and Strassburg C.P. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 363 9419 (2004) 1461-1468
38. Castro M., Krowka M.J., Schroeder D.R., et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 71 6 (1996) 543-551
39. McDonnell P.J., Toye P.A., and Hutchins G.M. Primary pulmonary hypertension and cirrhosis: are they related?. Am Rev Respir Dis 127 4 (1983) 437-441
40. Hadengue A., Benhayoun M.K., Lebrec D., et al. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 100 2 (1991) 520-528
41. Plevak D., Krowka M., Rettke S., et al. Successful liver transplantation in patients with mild to moderate pulmonary hypertension. Transplant Proc 25 2 (1993) 1840
42. Benjaminov F.S., Prentice M., Sniderman K.W., et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 52 9 (2003) 1355-1362
43. Mandell M.S., and Groves B.M. Pulmonary hypertension in chronic liver disease. Clin Chest Med 17 1 (1996) 17-33
44. Panos R.J., and Baker S.K. Mediators, cytokines, and growth factors in liver-lung interactions. Clin Chest Med 17 1 (1996) 151-169
45. Rockey D.C. Vascular mediators in the injured liver. Hepatology 37 1 (2003) 4-12
46. Robalino B.D., and Moodie D.S. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 17 2 (1991) 492-498
47. Krowka M.J., Porayko M.K., Plevak D.J., et al. Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Mayo Clin Proc 72 1 (1997) 44-53
48. Edwards B.S., Weir E.K., Edwards W.D., et al. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 10 6 (1987) 1233-1238
49. Krowka M.J. Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemmas. Hepatology 25 5 (1997) 1282-1284
50. Torregrosa M., Genesca J., Gonzalez A., et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Transplantation 71 4 (2001) 572-574
51. Krowka M.J. Pulmonary hypertension: diagnostics and therapeutics. Mayo Clin Proc 75 6 (2000) 625-630
52. Shapiro S.M., Oudiz R.J., Cao T., et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 30 2 (1997) 343-349
53. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334 5 (1996) 296-302
54. Minder S., Fischler M., Muellhaupt B., et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 24 4 (2004) 703-707
55. Halank M., Marx C., Miehlke S., et al. Use of aerosolized inhaled iloprost in the treatment of portopulmonary hypertension. J Gastroenterol 39 12 (2004) 1222-1223
56. Chua R., Keogh A., and Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant 24 4 (2005) 498-500
57. Krowka M.J., Mandell M.S., Ramsay M.A., et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 10 2 (2004) 174-182
58. Swanson K.L., Wiesner R.H., Nyberg S.L., et al. Survival in portopulmonary hypertension: mayo clinic experience categorized by treatment subgroups. Am J Transplant 8 11 (2008) 2445-2453
59. Kotloff R.M., Ahya V.N., and Crawford S.W. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 170 1 (2004) 22-48
60. Kett D.H., Acosta R.C., Campos M.A., et al. Recurrent portopulmonary hypertension after liver transplantation: management with epoprostenol and resolution after retransplantation. Liver Transpl 7 7 (2001) 645-648
61. Kuo P.C., Plotkin J.S., Gaine S., et al. Portopulmonary hypertension and the liver transplant candidate. Transplantation 67 8 (1999) 1087-1093
62. Huang T.W., Cheng Y.L., Chang H., et al. Education and imaging. Hepatobiliary and pancreatic: hepatic hydrothorax. J Gastroenterol Hepatol 22 6 (2007) 956
63. Wilputte J.Y., Goffette P., Zech F., et al. The outcome after transjugular intrahepatic portosystemic shunt (TIPS) for hepatic hydrothorax is closely related to liver dysfunction: a long-term study in 28 patients. Acta Gastroenterol Belg 70 1 (2007) 6-10
64. Ibrisim D., Cakaloglu Y., Akyuz F., et al. Treatment of hepatic hydrothorax with terlipressin in a cirrhotic patient. Scand J Gastroenterol 41 7 (2006) 862-865
65. Barreales M., Saenz-Lopez S., Igarzabal A., et al. Refractory hepatic hydrothorax: successful treatment with octreotide. Rev Esp Enferm Dig 97 11 (2005) 830-835